PARADIGM
LIVE

Serial Number

97583445

Owner

Kyra Clinical Corporation

Attorney

PERRY J. VISCOUNTY

Filing Date

Sep 8, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PARADIGM Trademark

Serial Number: 97583445

PARADIGM is a trademark filed by Kyra Clinical Corporation on September 8, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Kyra Clinical Corporation (4 trademarks)

175 S. 3rd Street, Suite 1000
Columbus, OH 43215

Entity Type: 03

PARADIGM HEALTH, INC. (17 trademarks)

175 S. 3RD STREET, SUITE 1000
COLUMBUS, OH 43215

Entity Type: 03

Trademark Details

Filing Date

September 8, 2022

Registration Date

Not Registered

Published for Opposition

January 14, 2025

Goods & Services

Business consulting and management in the field of data analytics for medical clinical trials, namely, management and compilation of databases in the field of medical clinical trials for business purposes; business consulting and management in the field of data analytics for medical clinical trials, namely, providing business information management services for such clinical trials; business information management in the field of data analytics for care coordination, and care navigation services in coordination with and/or on behalf of health plans, clinical trial sponsors, pharmaceutical manufacturers, physicians, hospital systems, patient advocacy organizations and/or other medical providers, all the foregoing in connection with medical clinical trials

Downloadable computer programs, and mobile device software for use by recruiting sites, principal investigators, clinical care teams, and/or patients for clinical trials, for use in planning, designing, implementing and/or managing clinical trials, and for use in conducting research, including patient journey analyses, cohort segmentation analysis, clinical trial design analysis, patient and population risk stratification analysis, safety and efficacy analysis, and/or health economics and outcomes research for clinical trials; application program interfaces, namely, downloadable software enabling software components to interact with each other for clinical trials

Providing temporary use of online, non-downloadable software for use by principal investigators, recruiting sites, clinical care teams, and/or patients for clinical trials, for use in planning, designing, implementing and/or managing clinical trials and for use in conducting research, namely, patient journey analyses, cohort segmentation analysis, clinical trial design analysis, patient and population risk stratification analysis in connection with medical clinical trials, safety and efficacy analysis in connection with medical clinical trials, health economics and outcomes research, and/or comparative effectiveness analyses in connection with medical clinical trials; application service provider featuring application programming interface software for enabling software components to interact with each other in connection with medical clinical trials; providing use of online, non-downloadable software to health care providers for patient evaluation, care navigation, quality improvement, and clinical research in connection with medical clinical trials; providing use of online, non-downloadable software to health care providers, patients, advocacy organizations, and/or other parties involved in patient care to support the design, start up, conduct, and/or analysis of medical clinical trials; software as a service (SaaS) solutions featuring software for operating and managing clinical trials by third parties; software as a service (SaaS) services featuring software for providing medical and scientific research information in the field of pharmaceuticals and clinical trials; computer software platform as a service (PaaS) featuring computer software platforms for operating and managing medical clinical trials by third parties; computer software platform as a service (PaaS) featuring computer software platforms for providing data analytics for medical and scientific research information in the field of pharmaceuticals and clinical trials; providing data analytics for scientific research for medical purposes in connection with medical clinical trials; clinical trial support services in connection with data analytics, namely data analytics for scientific research in the nature of coordinating medical clinical trial research for others; virtual consulting services in connection with data analytics for medical and scientific research related to clinical trials

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 7, 2026 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Feb 23, 2026 TMBN
OPPOSITION TERMINATED NO. 999999
Feb 23, 2026 OP.T
OPPOSITION DISMISSED NO. 999999
Feb 23, 2026 OP.D
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jul 13, 2025 ETOP
OPPOSITION INSTITUTED NO. 999999
Jul 11, 2025 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Feb 11, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 14, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 14, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 8, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 22, 2024 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Oct 23, 2024 ASGN
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 1, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 1, 2024 XELR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 26, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 26, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 26, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 26, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 26, 2024 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 9, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 9, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 22, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 9, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 9, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 9, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 9, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 9, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 6, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 5, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 5, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jul 5, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jul 5, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 22, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 14, 2022 NWOS
NEW APPLICATION ENTERED
Sep 12, 2022 NWAP